Transfection of C6 glioma cells with the bax gene and increased sensitivity to treatment with cytosine arabinoside

被引:17
作者
Vogelbaum, MA
Tong, JXX
Higashikubo, R
Gutmann, DH
Rich, KM
机构
[1] Washington Univ, Sch Med, Dept Neurol Surg & Neurol, St Louis, MO USA
[2] Washington Univ, Sch Med, Dept Radiol, St Louis, MO USA
关键词
apoptosis; chemotherapy; brain tumor; bcl-2 gene family; gene therapy; cell cycle; rat;
D O I
10.3171/jns.1998.88.1.0099
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Object. Genes known to be involved in the regulation of apoptosis include members of the bcl-2 gene family, such as inhibitors of apoptosis (bcl-2 and bcl-xl) and promoters of apoptosis (bax). The authors investigated a potential approach for the treatment of malignant gliomas by using a gene transfection technique to manipulate the level of an intracellular protein involved in the control of apoptosis. Methods. The authors transfected the murine bax gene, which had been cloned into a mammalian expression vector, into the C6 rat glioma cell line. Overexpression of the bax gene resulted in a decreased growth rate (average doubling time of 32.96 hours compared with 22.49 hours for untransfected C6, and 23.11 hours for clones transfected with pcDNA3 only), which may be caused, in part, by an increased rate of spontaneous apoptosis (0.77 +/- 0.15% compared with 0.42 +/- 0.08% for the vector-only transfected C6 cell line; p = 0.038, two-tailed Student's t-test). Treatment with 1 mu M cytosine arabinoside (ara-C) resulted in significantly more cells undergoing apoptosis in the cell line overexpressing bax than in the vector-only control cell line (23.57 +/- 2.6% compared with 5.3 +/- 0.7% terminal deoxynucleotidyl transferase-mediated biotinylated-deoxyuridine triphosphate nick-end labeling technique-positive cells; p 0.007). Furthermore, measurements of growth curves obtained immediately after treatment with 0.5 mu M ara-C demonstrated a prolonged growth arrest of at least 6 days in the cell line overexpressing bax. Conclusions. These results can be used collectively to argue that overexpression of bax results in increased sensitivity of C6 cells to ara-C and that increasing bax expression may be a useful strategy, in general, for increasing the sensitivity of gliomas to antineoplastic treatments.
引用
收藏
页码:99 / 105
页数:7
相关论文
共 42 条
[1]  
ALDERSON LM, 1995, CANCER RES, V55, P999
[2]   P53-PROTEIN ACCUMULATION AND GENE-MUTATIONS IN HUMAN GLIOMA CELL-LINES [J].
ANKER, L ;
OHGAKI, H ;
LUDEKE, BI ;
HERRMANN, HD ;
KLEIHUES, P ;
WESTPHAL, M .
INTERNATIONAL JOURNAL OF CANCER, 1993, 55 (06) :982-987
[3]   NEGATIVE EFFECTS OF WILD-TYPE P53 AND S-MYC ON CELLULAR GROWTH AND TUMORIGENICITY OF GLIOMA-CELLS - IMPLICATION OF THE TUMOR-SUPPRESSOR GENES FOR GENE-THERAPY [J].
ASAI, A ;
MIYAGI, Y ;
SUGIYAMA, A ;
GAMANUMA, M ;
ILHONG, S ;
TAKAMOTO, S ;
NOMURA, K ;
MATSUTANI, M ;
TAKAKURA, K ;
KUCHINO, Y .
JOURNAL OF NEURO-ONCOLOGY, 1994, 19 (03) :259-268
[4]   Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice [J].
Bargou, RC ;
Wagener, C ;
Bommert, K ;
Mapara, MY ;
Daniel, PT ;
Arnold, W ;
Dietel, M ;
Guski, H ;
Feller, A ;
Royer, HD ;
Dorken, B .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (11) :2651-2659
[5]   BCL-X, A BCL-2-RELATED GENE THAT FUNCTIONS AS A DOMINANT REGULATOR OF APOPTOTIC CELL-DEATH [J].
BOISE, LH ;
GONZALEZGARCIA, M ;
POSTEMA, CE ;
DING, LY ;
LINDSTEN, T ;
TURKA, LA ;
MAO, XH ;
NUNEZ, G ;
THOMPSON, CB .
CELL, 1993, 74 (04) :597-608
[6]   Diminished cell proliferation associated with the death-protective activity of Bcl-2 [J].
Borner, C .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (22) :12695-12698
[7]   Bax alpha perturbs T cell development and affects cell cycle entry of T cells [J].
Brady, HJM ;
GilGomez, G ;
Kirberg, J ;
Berns, AJM .
EMBO JOURNAL, 1996, 15 (24) :6991-7001
[8]   BCL-2 BLOCKS P53-DEPENDENT APOPTOSIS [J].
CHIOU, SK ;
RAO, L ;
WHITE, E .
MOLECULAR AND CELLULAR BIOLOGY, 1994, 14 (04) :2556-2563
[9]   The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas [J].
Chou, D ;
Miyashita, T ;
Mohrenweiser, HW ;
Ueki, K ;
Kastury, K ;
Druck, T ;
vonDeimling, A ;
Huebner, K ;
Reed, JC ;
Louis, DN .
CANCER GENETICS AND CYTOGENETICS, 1996, 88 (02) :136-140
[10]  
DOLE M, 1994, CANCER RES, V54, P3253